Additionally, the co‐administration of the SIRT2 inhibitor SirReal2 with the PI3K/mTOR inhibitor VS‐5584 exhibited enhanced anti‐tumor properties against AML cells. The gene discussed is SIRT2; the disease is acute myeloid leukemia.